prazosin has been researched along with Infarction, Middle Cerebral Artery in 1 studies
Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.
Infarction, Middle Cerebral Artery: NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X | 1 |
| Zhao, C | 1 |
| Li, X | 2 |
| Wang, T | 1 |
| Li, Y | 1 |
| Cao, C | 1 |
| Ding, Y | 1 |
| Dong, M | 1 |
| Finci, L | 1 |
| Wang, JH | 1 |
| Liu, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessing Target Engagement of Terazosin in Healthy Adults[NCT04551040] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-03-26 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for prazosin and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Terazosin activates Pgk1 and Hsp90 to promote stress resistance.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Apoptosis; Cells, Cultured; Cytokines; HSP90 Heat- | 2015 |